A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
Sarah P. Blagden(Churchill Hospital), Mark R. Middleton(University of Oxford), L. Rhoda Molife(Royal Marsden NHS Foundation Trust), Lakshmi Vasist(Research Triangle Park Foundation), A Seebaran(Churchill Hospital), Miranda Payne(Churchill Hospital), Andrew Protheroe(University of Oxford), Jeffrey P. Hodge(Research Triangle Park Foundation), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Steven J. Kathman(Research Triangle Park Foundation), Mohammed M. Dar(Queen's University Belfast), Chester L. Bowen(Research Triangle Park Foundation), Daphne Williams(Research Triangle Park Foundation), Alison Reid(Royal Marsden NHS Foundation Trust)
Cited by 82
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k